Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues
Preclinical efficacy evaluations of XK-469 : Dose schedule, route and cross-resistance behavior in tumor bearing mice
Lack of in vitro – in vivo correlation of a novel investigational anticancer agent, SH 30
Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome – Recall following different chemotherapy agents
Phase I study of JM-216 (an Oral platinum analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies
Phase I clinical trial of 5-fluoro-pyrimidinone (5fp), an oral prodrug of 5-fluorouracil (5fu)
Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus
Phase II trial of pegylated-liposomal doxorubicin (doxil™) in renal cell cancer
Phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy – southwest oncology group study
Phase II trial of amonafide in central nervous system tumors : A Southwest Oncology Group Study
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II : a Southwest Oncology Group Study
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer : a Pilot Study
Instructions for Authors